Q3 2025 Evogene Ltd Earnings Call
Welcome to evirgen third quarter 2025 results conference call. All participants are at present in listen-only mode. Following management formal presentation, we will open the question and answer session. You may send questions via check, please type your name and Company. Before your question, as a reminder, this conference is being recorded, November 20205.
Before we begin, I would like to caution that certain statements made during this earnings conference call by Evo and management will constitute forward-looking statements that relate to future events.
Statements that are not statements or historical facts. May be deemed to be forward-looking statements.
such forward-looking statements may be identified by the use of such word as believe expect anticipate should plans estimate intent and potential or words of similar meaning
We are using forward-looking statements in this presentation, when we discussed our value drivers, commercialization efforts and timing product development, and launches estimate Market sizes, and Milestones pipeline, as well as our capabilities and Technology.
Such statements are based on current expectations estimates projections and assumptions describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guaranteed of future performance.
We deserve caution that certain important factors, may affect the company's actual results and could cause such results to different material from any forward-looking statement that may be made in this presentation, therefore, actual future results, performance, or achievements, and Trends in the future. May differ materially from what is expected from applied by such forward-looking statements, due to a variety of factors, many of which are beyond their control, including without limitation, the current war between Israel, and Hamas and any other adverse impact that it may have on economic activity in Israel.
Due to the calling enough of a larger number of Reserve soldiers or the incurrence of death to pay for the high cost of the war and any accompanying. Future uncertainties for the security of the company's operations in southern Israel, as well as those additional factors describing greater detailing evidence annual report on form 20f and in other reports evidence files with and furnishes to the Israel security authorities and the US Securities and Exchange Commission. Including those factors under the head and risk factors expect is required by applicable Securities Law. We disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revision to any statement that may be made to reflect future events and developments or changes in expectation estimates, projections and assumptions. The information contained here.
and does not constitute a prospectus or other offering documents nor does it constitute or form part of any invitation or offer to sell or any solicitation of any invitation or offer to purchase or subscribe for any Securities of the company nor should the information or any part of it or the fact of its distribution from the basis of
Or be relied on in connection with any action contract or commitment relating thereto or to Securities of the company.
The trademarks include hearing are the property of the owners thereof and are used for reference purposes, only
Statues should not be construed as an endorsement of a product or services with us on the line will be offered have the president and CEO of Evan, and your own health CFO of averages.
Now I will return the call over to offer her Mr. Hav, please go ahead.
Thank you for joining Evans. Third quarter 2025 analyst call
In today's call.
I'd like to focus on the company's new strategy.
Which I partly shared at our previous quarterly course.
And its current implementation.
I will also provide an update.
On our expectation, to start rating the business benefits of this strategic shift over the coming year,
Following my remarks our CFO, euron dad.
We present the financial results and we will then open the call for questions.
But as usual, I will start with the financial highlights.
During the first 9 months, ending September 30 2025.
Everon advanced its strategic transition toward establishing itself as a leader in computational chemistry, with a focus on the generative design of small molecules for the pharmaceutical and agriculture industries.
As part of this new strategy,
The company executes.
An organizational change and cost reduction plan.
Most of which was completed by the end of the second quarter.
In the third quarter results, the total operating expenses netted approximately $2.9 million.
Compared to 6.6 million in the same period of 2024.
This new expense level is expected to be maintained going forward.
The financial results of Lviv, bio.
A subsidiary.
For the 9 and 3 months, ending September 302025.
They are presented as a single line item in evidence consolidated P&L statement for 2025.
Its results are including under the line titled.
Income.
Or loss from discontinued operations, net.
this accounting presentation includes the sale of the majority of labid BIOS activities to ICL which was completed in July 2025, and together with the sales of Micro Boost for a generated income of approximately 7.9 million in the third quarter of 2025
In the 9 months, ending September 30th 2025 revenues amounted to approximately 3.5 million compared to 4 million in the same period last year.
the decrease was primarily driven by lower revenue from act plans, activity, which included,
A 1-time payment from buyer during the first quarter of 2024.
Partially offset by an increase in sales generated by castera.
Total research and development expenses in the 9 months. Ending September 30 2025 were approximately 5.9 million compared to approximately 9.8 million in the same period of 2024. The decrease its primarily attributed to a reduction in biomass and
Certain marketing expenses in the nine months ending September 30, 2025, totaled approximately $1.1 million, compared to approximately $1.6 million in the same period of 2024.
The decrease is mainly due to reduction in headcount across the subsidiaries.
In the 9 months, ending September 30 2025.
Total operating loss was approximately $8.8 million compared to approximately $15.3 million in the 7th period of 2024.
This decrease is mainly due to the decrease in the subsidiaries and Evo activity.
As of the end of the third quarter of 2025, the company's cash and short-term bank deposit balance was approximately $16 million.
This cash balance reflects the proceeds from the sale of labib BIOS assets and the Micro Boost AI for architect engine to IPL.
The following are the business highlights of our subsidiary and related parties in the past quarter.
lab bio completed the transfer of its team and the majority of its activity to ICL,
its collaboration agreement with an existing partner continues with positive results.
The distribution of funds to its shareholders, with Aerogen as the majority holder, is advancing.
No, additional activities are expected.
Bionic clinical trial continues according to plan.
And is expected to be completed in early 2026.
Currently only 1 patient is in the trial.
And the efforts to secure Partners to lead. Biomass current development program. Continue
No additional activity are expected.
Last week castella partnered with fantini to Advanced agricultural mechanization.
For scalable commercial Castle, farming.
The collaboration focus on integrating high, yield customer varieties with Advanced mechanized Solutions.
Including harvesting.
And threshing Technologies.
At planus.
Underwent organizational, restructuring.
Including the completion of Workforce reduction.
Efforts related party, finally food, which grows the Kaza in protein in potatoes.
Announced raising 1.2 million dollars led by CBC group.
And signed a commercial agreement with it.
Now.
I would like to continue with a new strategy and its implementation which include act plan with activity for the agriculture industry.
The following slides reflect Eens' new messaging and appearance, supporting its new strategy.
At everon. We are on an ongoing mission to redefine the future of Science and business.
by harnessing, the power of our proprietary generative, AI Tech Engine campus, AI,
We design novel, groundbreaking small molecules.
Highly potent and precisely optimized across multiple parameters.
To transform the pharmaceutical and add chemical Industries.
Our goal is not just innovation, but meaningful, beneficial impact for our world.
Headlining. This slide is the phrase real world, Innovation.
What do we mean by it?
1 of the greatest challenges in developing product in lifetimes.
For pharmaceuticals to add chemicals is the gap between real world challenges and Innovative scientific discovery.
Anyone involved in life science product development knows this challenge. Well,
It's reflected in the high failure rate of products that start full of innovative promise.
But ultimately, for short act of one or more critical criteria that often emerge only in the later stages of development.
We Believe now is the time for change for Bridging the Gap between Innovation and real world impact.
The key lines in harnessing, the possibilities of the computational revolution.
Transforming Our World and above all in unlocking, the power of AI.
Today's computational capabilities allows for simultaneous analysis of countless parameters, achieving a level of scientific depth.
that was once behind, which
They Empower us to design solutions that integrate scientific innovation with commercial viabilities.
Pushing beyond the limits of traditional trial and error product development.
Computational technology serve as the bridge.
Connecting scientific discovery to Commercial Success.
And this is exactly what we focus on.
We call our approach real-world innovation.
Epogen is structured on 3, inter pillars.
Our groundbreaking Gene, AI best technology.
Campus AI serves as a competitive advantage for our offerings in the pharmaceutical and agriculture industries.
Second, our established activity in agriculture through our subsidiary at Planus, where we have already achieved results and collaboration with leading global companies in the development of a chemical product. And
Our recent expansion into the Pharma industry where campus AI significantly increase the likelihood of the discovery of Novel molecules.
With the highest potential to become breakthrough commercial drugs.
I will begin with brief introduction to Compass AI, which is at the core of our operations.
To understand the unique value of Campus, AI.
It is essential to consider the background of the product development process and its inherent challenges.
Such as drug or pesticides is developed.
It started with identifying the target protein. We aim to inhibit
followed by searching for a chemical molecules capable of binding to it from an almost infinite number of possibilities.
During the discovery and optimization phase, the objective is to design the most promising candidate for advancement in the next stage of development.
These later stages are time-consuming and costly, so choosing wisely early on is crucial. It's also worth noting that once these advanced stages are reached, the chemical structure of the molecules is basically set. This is the version that, hopefully, will eventually make it all the way to market.
Therefore, very early in the process, right after optimization. We commit to the molecule, we believe it has the highest probability of becoming the final product.
The outcome of this process is often frustrating.
Statistically only a small fraction of promising molecules that make it into advanced development, actually, reach the market.
Success rates are usually somewhere between 3% and 10%, depending on the industry.
This naturally raised the question.
What caused the success rate to be so low?
A major reasons for low success rate is that a product must meet many often conflicting, parameters to reach commercialization.
Traditional methods for selecting molecules and addressing, multiple parameters are very limited as a result. Early development usually optimized only a few parameters, 1, parameters at a time, creating a major bottleneck to Commercial Success.
Overcoming this challenge presents a significant strategic opportunity.
Today advanced in computational Technologies.
Allowed for the simultaneous optimization of multiple parameters with the potential to greatly improve development efficiency and success rate.
That brings us to campus AI.
The Cutting Edge Tech Engine developed here at eoin.
Built to transform the way. We design small molecules that are precisely tailored to specific. Target proteins.
What makes our approach? Truly unique is not just the molecules we design.
But the intelligence behind them.
Each molecule must overcome a complex web of scientific Regulatory and Commercial challenges.
To become real product. A molecule has to do more than just work.
It must Excel across multiple.
Dimensions simultaneously.
And that exactly what campus AI was built to achieve.
Our engine designs molecules that meet 3 critical requirements.
High potency molecules that strongly and effectively modulate their target protein.
Novelty expanding into novel chemical space, ensuring the creation of strong, defensible intellectual property.
And multi-parameter excellence molecules that perform across the many requirements needed for real-world commercial success.
With compass AI.
We are not just designing molecules, we are designing the next generation of breakthrough products.
Closing the gap between Innovation and Market impact.
That's the power and the promise of Campus AI.
We are advancing a multi-year development program continuously adding new capabilities to our generative AI Tech Engine.
Continues to improve.
The more the system is used the smarter and more accurate, it becomes.
To accelerate campus AI development process. We are collaborating with major technology companies such as Google Cloud as disclosed in May this year and we intend to continue doing so additionally, we intend to explore the possibility of making certain parts of our technology accessible to researchers.
Through such companies, which have a broad market reach.
Of course, we will be happy to update you on this developments in the future.
Our vision come to life.
So, the technology we have developed.
Now, I'd like to present the implementation of our technology through our Agriculture and farm activities.
Starting with agriculture.
The fields we entered back in 2018.
Through the establishment of our subsidiary act plans.
Since then, Acknowledge has achieved significant milestones.
Including strategic collaborations with leading industry players.
Such as buyer and cortiva.
Agriculture is a huge global market valued in 2024 at $79 billion, including three main segments: herbicides, insecticides, and fungicides.
A single product in this space can generate anywhere from hundreds of millions to billions of dollars in sales annually.
The industry is in great needs of new products, yet developing them comes with significant challenges.
An increase in tax resistance and regulatory requirements.
And urgent need for new model of actions.
and the decreased rate in discovery of new pesticides, due to lack of innovation,
To address the challenges of developing new products in additive chemistry, revolutionary technologies are needed.
Computational chemistry, can drive real world impact in agriculture? And this is the mission of act plans. Everon wholly owned subsidiary.
At Plano, we discovered and optimized candidates for crop protection products and have a robust product development pipeline through collaborations with leading global agriculture companies, as well as internally founded programs.
We are very proud of our ACT plans and achievements.
Reflected in its strategic collaboration with 2 world, leading companies, buyer. And cortiva.
Boss collaborations focus on developing new herbicides, each targeting a different protein that represents a novel mode of action.
This Innovation is essential to addressing the growing resistance of past to existing Solutions. The plant images shown in this slide, clearly demonstrate the effect of the small molecules being Advanced through those collaborations.
Act Planners is also advancing independent projects within its internal pipeline, with its main focus today on developing fungicide candidates against Septoria.
The founders are causing major damage to field crops, especially with.
Eggplants already have several small molecules showing very promising results in lab tests.
Which are now moving to Greenhouse trial to test their performance on plants.
Looking ahead.
At Plano, we plan to further strengthen and expand our collaboration with existing partners.
Establish new Partnerships, leveraging act plans Flight Plan Innovations.
And broaden the scope of programs within its internal development portfolio.
These initiatives are expected.
Cash inflows.
For the company through upfront payment R&D reimbursement and it's our products Advanced through development Milestone payment and potential royalties.
To providing further update on both collaborative efforts and internal pipeline progress.
Now, I will continue with our efforts to capture the value of our Tech Engine campus AI in the Pharma industry focusing on the market. Segments of drugs based on small molecules.
Why are small molecules based drugs? Such lucrative opportunity and why do we believe now is the right time to leverage our technology for it?
Small molecule-based drugs represent nearly 60% of the global pharmaceutical market, valued at approximately $1 trillion.
780 billion dollar.
Even more exciting is the current momentum of AI designed small molecules that are advancing through various companies Pipelines.
More than 60 new candidates with an expected annual growth rate exceeding 150%.
This rapid expansion is expected to drive the AI drug discovery market to nearly $190 billion by 2034.
Ethnic previously, mentioned the traditional process of developing drug based on a small molecule.
Is expensive.
Lengthy and has a low success rate.
This slide illustrates the high numbers of failures that occur during the transition from one stage of clinical trial to the next.
We expect that a smart use of our Tech engines campus AI will lead to the initiation of clinical trials for highly active innovative.
Small molecules.
Which most importantly meet the maximum number of the defined drugs key parameters.
As a result, we expect the probability of successfully progressing from 1 development stage to the next to improve.
And the number of candidates that complete the development process and become successful, commercial products will increase significantly.
To capture the value of Campus AI offering in Pharma.
Our business strategy is designed to maximize potential while minimizing risk.
We hope to partner with leaders in Pharma biotech companies and Academia that bring domain specific knowledge.
Forming collaboration agreements.
Through these strategic Alliance, we aim to co-developed Innovative products.
The expected upside for evidence seems to come from R&D fees, milestone payments, and the revenue-sharing mechanism of the end product.
In August.
our farmer division announced a collaboration with Professor Ehud gazit of Tel Aviv University to develop new Therapeutics for metabolic disease, linked to the self assembly of small metabolites,
Such as Carrillo.
And gout.
The partnership combines Evo gens. Campus AI generative design platform with Professor gazit expertise in molecular self assembly to discover and optimize novel small molecules that can inhibit. Harmful metabolites aggregation.
This collaboration aims to accelerate the development of first in-class Therapies.
That addresses, the underlying molecular causes of accumulated, metabolic disease.
Offering New Hope to patients worldwide.
This collaboration.
exemplifies, the type of strategic partnership, we are pursuing
Leveraging evidence Advanced computational capabilities, alongside existing scientific knowledge to create meaningful synergies that can drive breakthrough discoveries in drug development.
Further strengthening.
Of our unique technological Edge.
We Believe such partnership will provide the validation and visibility needed to enable broader and more complex collaborations with leading biotech and pharmaceutical companies opening new growth opportunities for aen.
We look forward to providing future updates on our collaborative efforts.
To summarize evidence strategy.
We are using Compass AI, which is at the core of our offering and our main competitive advantage to drive real world Innovation for 2 strategic markets.
Farmer for the development of small molecule based drugs.
Agriculture for the development of crop protections chemicals.
To realize this Vision we operate through Pharma division, focused on pharmaceutical applications and so our wholly owned subsidiaries at planus focused on a chemical Solutions. Each develops its products either in collaboration with leading global companies or independently.
in the near future, we expect the following
continuing to strengthen and expand campus. Ai and maintaining our technological Edge signing additional collaboration agreement with biotech and later on with Pharma partners for small molecules drug development.
And expanding collaborations with existing and new leading, add team companies while growing act planus internal crop protection pipeline.
With that, I conclude my part, and I will now hand the call to our CFO, Yaron Eldad, to present the financial results.
Thank you, offer.
The financial results for the first 9 months of 2025, and the capital gain of LV Bio, a subsidiary of Evogene, are presented as a single line item in Evogene's consolidated P&L statement for the first 9 months of 2025.
Its results are included under the line, titled income or lost from discontinued operations.
This accounting treatment reflects the classification of Levy Bios operations and its capital gain as discontinued.
Following the sale of the majority of its activities to ICL which was completed in July 2025.
During the first half of 2025 eigen implemented, a cost reduction plan, most of which was completed by the end of the second quarter.
The impact of these reductions is reflected in the first 9-month results.
As of September 30th, 2025 evogen Health Cash Cash, equivalents and shortened Bank deposits of approximately 16 million dollars.
The consolidated cash usage during the third quarter of 2025, excluding the cash generated from the sale of the majority of Rosie Bio's assets.
And the sale of Micro Boost AI for a 2.
Was approximately 3.5 million.
excluding the Vio and bionica everon, and its other subsidiaries used approximately 2.3 million dollars in cash during the third quarter of 2025,
Revenues for the 9 months of 2025 were approximately 3.5 million compared to approximately 4 million on the same period the previous year.
Reflecting a decrease of approximately half a million dollars.
The decrease was primarily driven by lower revenue recognized from a pen activity, which included a one-time payment from Bayer during the first quarter of 2024.
And revenue recognized from the collaboration agreement was called Dia, partially offset by an increase in seat sales generated by Castera.
During the first quarter of 2025.
The decrease was mainly due to reduced seed cells generated by Castera during the third quarter of 2025.
Research and development expenses. Net.
of non-refundable, grants for the 9 months of 2025 were approximately 6.2 million a decrease of approximately 3.6 million compared to 9.8 million in the 9 months of 2024,
the decrease was primarily due to reduce R&D expenses in biomass and the cessation of canonic operation at the beginning of 2024
In the third quarter of 2025 R&D expenses were approximately 1.4 million dollars down from approximately 3.3 million dollars in the same period of 2024.
This this decrease is mainly attributed to decreased expenses in bionica
Sales and marketing expenses for the 9-month of 2025 where approximately 1.2 million dollars, a decrease of approximately 400,000 dollars compared to approximately 1.6 million dollars in the same period last year.
The decrease was mainly due to reduction in evogen, act plans, and biomer. Personnel costs
Sales and marketing expenses. For the third quarter of 2025, were approximately dollars reflecting a slight decrease of approximately.
100,000 dollars compared to approximately 500,000 dollars in third quarter of 2024.
General and administrative expenses for the 9 months of 2025 decreased to approximately 3.4 million from approximately 5.7 million dollars in the same period last year.
This decrease is mainly attributable to expenses recorded during the 9-month period of 2024 related to a provision. For that full debt for 1 of casturos seat suppliers as well as transaction costs associated with evidence fundraising in August 2024.
General and administrative expenses for the third quarter of 2025 decreased to approximately $1.1 million compared to approximately $2.8 million in the same period of the previous year.
Primarily due to decreased expenses in castera and evogen as mentioned above.
Other income of approximately dollars was recorded in the first quarter of 2025 as part of the accounting treatment related to a subly agreement.
The decision to see is a canonic operation in the first half of 2024, which resulted in other expenses of approximately $500,000, primarily used for the impairment of fixed assets recorded in the first quarter of 2024.
The operating loss for the 9 months of 2025 was approximately $8.8 million, a significant decrease from approximately $16.3 million in the same period of the previous year.
Mainly due to the decreased operating expenses, partially offset by the decreased revenues. As mentioned about
The operating loss for the third quarter of 2025 was approximately 2.7 million dollars a decrease from approximately 5.9 million dollars in the same period of the previous year.
Primary use to the decreased operating expenses, partially offset by decreased revenues as mentioned above.
Financing income net for the 9 months of 2025 was approximately 744,000 compared to financing expenses. Net of 448,000 in the same period of the previous year.
The increase in financing income is mainly associated with accounting treatment of pre-funded warrants and warrants issued in August 2024 fundraising.
Nothing expensive net.
Of approximately 881,000 in the same period of 2024.
Financing income net. For the third quarter of 2025 was approximately 12,000 compared to financing expenses, net of approximately 821,000 in the same period of the previous year.
The increase in financing income is mainly associated with accounting treatment of pre-funded warrants and warrants issued in August 24 function as mentioned above.
Income from discontinued operations net, for the 9 months of 2025 was approximately 5.7 million compared to a loss of approximately 2.2 million dollars in the same period of 2024.
for the third quarter of 2025,
Income from discontinued operations was approximately $7.9 million, compared to a loss of approximately $1.5 million in the quarter of the previous year.
These amount primarily reflect the financial results of your bio and expenses related to the development and maintenance of Micro Boost AI for egg.
Which are presented as a single light line item in the Consolidated statements of profit and loss.
Following the sale of the majority of the re bios assets as well as evidence Micro Boost AI for a 2 CL.
The company recognized a gain on sale of approximately 6.4 million which is also included in the income or loss from discontinued operations. Net for the 9 months and 3 months, period ended September 2025.
All prior period amounts have been, reclassified to confirm to this presentation.
In the net loss for the 9 months of 2025 was approximately 2 and a half million dollars compared to approximately 18 million dollars in the same period last year.
The 15.5 million dollars, decrease in net loss was primarily due to decreased operating expenses.
Income derived from discontinued operations due to the asset sale to ICLN net.
And increased Financial income net partially offset by reduced revenues.
The net income from the third quarter of 2025 was approximately 5.2 million compared to a net loss of approximately 8.2 million dollars in the same period last year.
This improvement was primarily used to account for income derived from discontinued operations, net, due to the asset sale to ICL.
decreased operating expenses and increased finan financing income, net partially of set by reduced revenues net as mentioned about,
Operator.
Thank you, ladies and gentlemen. At this time, we will begin the question-and-answer session. In order to send a question, please use the chat button located at the bottom of your screen. Type your full name and your company's name before your question.
The first question.
Has the levels of interest in AI, Champions increased. Both the recent Nvidia, early Lily AI drug, Discovery partnership. Also, could you please elaborate why everence proprietary database? Should Garner? Similar interests from others in Pharma and Technology Industries?
I think that uh, uh, we are offering something very unique. Um I can share with you that we participate in a conference in Europe. Uh, last month uh and uh we see um, increased interest in what we are presenting to potential Partners. Um, it's a it's I think it's um we are only in 1 year uh in this area of the presenting, our campus technology for the farming Industries, and we see, uh, increasing interest on in what we are doing. And we shouldn't forget that in the a industry. Uh, we already have a certificate for our agreement with by and forever, which you can imagine that the value evaluate validate our technology before they engage in this, this collaboration agreement. Uh what is unique about neoen for my perspective, this multi-parameter approach, it's 1 then uh the second
Is that?
In everon the people that are working with computational part, the they have a PhD degree in genomics and this is the type of people that can design uh from search scratch and AI Tech Engine. And this is what is called foundational model and we did it together with the Google team. Uh and we 6 to create a very unique dedicated AI engine uh the
From the beginning, it was designed for a small molecule discovery on optimization. This is something that is not existing other places. And in addition, the way that we are utilizing our technology while we integrate, every piece of information coming from our partners is also good as in a very, uh, uh, different position compared to other companies. Because we don't believe in, in 1 size, fit, all approach, where you are, developing a specific technology and you are using it. For all the companies the same way in our case, we modify the technology uh uh, for each partner, according to the specific need of the specific program. We are engaged. So yes, it might take a little bit longer, but the performance of what we deliver is expected, to be much higher than uh uh uh, the pro of 1 size fit for. So I think that the our technology
Is offering something different uh and and as time is going by and we have more and more meetings with potential Partners uh our I believe and and is is getting stronger and stronger that we are coming with something, which other companies is not offering these days.
The next question: How close are you to unlocking partners with AI Chambers?
So f.
Of interest in in what we are offering it's a it's a meetings. We participate in the conference. We participate in the early years at the beginning of the years. Uh we return with an a small number of potential candidates. Now it's much the, the list of potential candidates in qu significantly and best on this. Uh, I I believe that we hopefully will start to announce on more additional collaborations agreements with biotech companies, uh, at the beginning of the next year, uh, and um, we start to hear more and more on new collaborations. Uh, and hopefully with the starting with the, um, small plastic companies, maybe even some organic economic institution, but later on it will be, uh, midside. But the companies and, and in our Target, at the end of the day is also to engage with farmers.
Companies, uh, uh, with a significant significant collaboration agreement. But this doesn't take a, a, a little bit more time. But as I said, uh, small Banker companies, uh, will start to, hopefully, to be able to announce such collaboration at the beginning of next year.
The next question, last quarter, you spoke to doing more IR to drive, awareness to the company, but very little seems to be done what the eel strategy going forward and can we rely on it being implemented in short order?
The answer to this question is yes. And what—how is it connected to the question that was just raised?
Uh, I think from this analyst call now, we present, you know, the first time, uh, uh, our president, the new presentation, uh, uh, in an analyst call we, where we are describing een in the new structure, uh, focusing on campus AI, uh, the utilization of this technology in the A and in the farmer and the corporation that we engage, and from here on on, this will be the main uh, um, uh messaging. The company would like to share with investors. Yes. We of course we will continue to talk about our our subsidiary Cera but the main focus will be on what adjustment of described and we are now and we we are planning to initiate uh um a row shows and and the and participate in conferences. Uh, next year, uh, not necessarily just IR
Meeting with investors but also meeting with in, in a professional uh, events. Um, and I think that starting from actually, from from even from December. We are planning that ever the name and the, the new story of Evo Jen would be at the other, uh, and, and the hopefully will start to see more and more
Uh, um, events. I our events, uh, that we will be involved with.
The next question, could you highlight upcoming Catalyst over the coming 6 till 12 months?
Specifically, when could we expect the first partnership?
so, I think
That these three types of press releases are related to the Evogene new strategy, new collaboration, and, in the end, the farmer. This will be in the form of division, meaning that additional biotech companies will use our technology.
Uh, uh, uh, to identify to recover and optimize small molecules for the specific targets. Uh, then expand expansion of existing collaboration, or new collaboration in the A and the vision I'm talking here. Of course, about act planets, uh, and third. And this is something that I think is quite important for us to mention. Um, exactly as we engage with Google in building an important piece in our Tech Engine. Uh uh I'm expecting and and hoping that there will be additional announcements like this 1 uh, with companies like Google the same size of Google or
Also, maybe with Google and, and I think that our belief is that we definitely should accelerate the development of the campus AI, uh, uh, in group collaboration with the company, um, like Google, uh, in order to, um, keep our competitive advantage in the future as well.
The next question. What type of Revenue level can we expect for customer seeds in Q4 and for 2026?
We can disclose, uh, this information. Uh, what I can say is that, uh, uh, about castera, there are now talking with, uh, um, I mean companies, uh, strategic companies in in the field of the customer oil, uh, companies that can really have a significant effect on the company Revenue in the future. Uh, we bring this discussion, will materialize, of course, we will share this information with our investors, but I think this is a good news, uh, that if, in the past we were talking about specifically, 1 partner that we already discussed his name, he and I, but I think that today, uh, we, uh, believe that there is additional opportunity, uh, for companies that can have the same effect.
On the, on the castera that we are now talking with them. Uh,
More than 1 like this. So when, when this discussion of materializing to agreement,
I will, of course, be more than happy to share this information with our investors.
to all your other times at effigy,
Uh I think that you know, this is this is a very um interesting question. I think that
For many, many years everon was focusing, mainly on the other sector.
And I think that we fixed it to, uh, go through some significant technology breakthroughs.
but,
From different region, and I don't want to get into it. Uh, the, the aspect sector don't give you a financial credit, uh, to such an achievement from different different reason. Uh, I think in the Pharma, uh, the situation is different. And, and I think that first, the fact that we are focusing on on the farming industry, uh, uh, uh, uh, yes, we are still in the a industry with respect to eggplants, but but our main purpose is going to be on on the farmer industry. So I think this is the right decision for evogen.
In addition, uh, the type of people that are working here in the everon is is people that work at PhD degree. Uh and this is very important. We also when you are talking about AI because if you are really want to be a player in the AI,
Uh, we don't have the respect to first degree or second degree. Uh, it's not enough you you need to have a much broader understanding in computational science in order to to be uh uh, to act as a a player in AI industry. So uh, I truly believe that we have the right people for the right challenge. Uh, and
Again, based on initial validation, we conduct here in Everon based on the discussion. We conduct now in the last bio conference.
I would, I would like to say the following if we will succeed.
To mimic.
The same success, everon.
Demonstrate in the ad industry between 16 to do so in the farmer industry.
Our company will be something that everybody will be proud to participate in on our journey.
We, we, we, we, we have been there with success to work with all the world, all the big companies in the far in the, in the industry. I hope that we will be able to do exactly the same, but this time the financial rewards will come after this, uh, uh, uh, um, efforts that we are going to invest.
There are no further questions at this time. Mr. Jave, would you like to make your concluding statement? Yes, I would like to thank everybody for participating in this analyst call for me, it was a very unique presentation where we present the for the first time. The new Everton story with the new presentation and I really hope that in the next analyst call. We will have much more to share with you, uh, along the, the timeline is just now described
Thank you. This concludes the third quarter 2025 results conference call for Evogene Ltd. Thank you for your participation. You may go ahead and disconnect.